CT
Canntab Therapeutics Limited
CTABF · OTC
$0.00 +0.00% (+$0.00)
Market Cap $5.30K
P/E Ratio -
Div. Yield -
ROE -
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
3/9Valuation
100 /100
Cheap P/S 0.02x
EV/EBITDA N/A
P/B N/A
Growth
54 /100
Stable Rev. growth 6.92%
FCF growth N/A
Book val. growth N/A
Profitability
0 /100
Weak Net margin 1,257.55%
Op. margin 1,419.41%
FCF margin 1,000.14%
Quality
2 /100
Poor ROA 129.35%
Asset turnover 0.10x
ROIC 230.41%
Debt
52 /100
Moderate Int. coverage -5.51x
Net debt/EBITDA -0.46x
Current ratio 0.57x
Stability
43 /100
Moderate EPS volatility 30.33%
Profitable years 0
Beta 1.42x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CTABF
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Richard C. Goldstein
Employees
-
Headquarters
Markham